I would assume one of the the bigger changes will more than likely be the addition of the hypomethylating agents in the AML trial. The last data we saw pointed to the company needing to make some changes if they still wanted to pursue frank relapse. Given that the trial is already underway I would imagine the FDA is a bit more involved in these changes.
Regardless of the changes I know Vera has been working on this for quite some time. I hope the update shows how much time went into this and it is well received.
News 
Market Data 
Discover 
AI
